This Week’s Question:
Comes from this weeks newsletter Item#2
Combining rosiglitazone, metformin, and insulin aspart
improved glucose metabolism in obese type 2 diabetic patients compared
with mixed insulin alone, according to the results of a open-label,
randomized trial published in the December issue of Diabetes Care.
Which of the following would
not be a benefit of the above triple therapy?
1. Improved peripheral
insulin sensitivity
2. Improved hepatic insulin sensitivity
3. Improved glycemic control
4. Improved weight control
